They joined Lyonbiopole’s membership
Creation : 2021 (2023 en france)
Employees : 2
Place : Lyon
Activity : Biotech
Who ?
Meddenovo Drug Design specializes in the creation and realization of drug candidates through a technology platform that synergizes physics-based methods and artificial intelligence. Our mission centers on reducing the false positive rate in drug development, a critical factor in avoiding unforeseen costs. Our innovative approach paves the way for our partners to explore unconventional drug candidates and novel targets effectively.
Our bioAIM software stands out by transforming potency prediction, establishing a new benchmark for accuracy and dependability in computational drug discovery. This tool is instrumental in our ability to anticipate the interaction of the most unconventional molecules with high precision.
Complementing bioAIM, focAIyze leverages AI to generate intelligent molecular libraries. This technology excels at predicting drug-like attributes, thereby facilitating a more efficient selection process for potential drugs.
Together, these advanced tools empower Meddenovo to overcome complex challenges in drug design, offering our partners unique solutions and a competitive edge in the fast-evolving pharmaceutical landscape.
Why joined Lyonbiopole ?
Lyonbiopole was highly recommended to us by numerous contacts in Lyon, recognized for its excellent reputation in promoting collaboration. In drug discovery, collective effort is essential – success relies on merging diverse expertise and resources. Lyonbiopôle is essential in this regard, because it excels at bringing people together. Their events, such as Private Inv€stment Day, allow for rapid integration into a strong network, which is invaluable for us at Meddenovo. Their respected name not only provides credibility but also instills trust in our customers and partners, reinforcing our commitment to developing reliable drug candidates.
Ilke UGUR MARION – Cofounder & Managing Partner
